Researchers at SMU found that decreasing TIGAR protein levels in cervical cancer cells makes them more responsive to chemotherapy drugs at low doses. This discovery offers a potential new treatment approach for HPV-induced cervical cancer with fewer side effects.
Researchers found thiopurine-induced mutations in leukemia cells, inactivating a DNA repair process and making the cancer resistant to multiple chemotherapy drugs. This study provides direct genomic evidence of chemotherapy-induced drug resistance mutations in pediatric cancer.
A study published by The BMJ found that remote 24-hour monitoring for cancer patients receiving chemotherapy significantly reduces symptom burden, anxiety, and work limitations. Patients who used the system experienced improved quality of life and reduced supportive care needs.
Hematopoietic stem cells use RNA from junk DNA to enhance activation after chemotherapy, leading to increased inflammatory signaling and faster blood cell production. This mechanism helps improve blood regeneration after chemotherapy.
A meta-analysis found that obese patients with colorectal cancer receive lower cumulative doses of adjuvant chemotherapy relative to their body surface area than non-obese patients. This may explain the poorer survival rates observed in obese patients receiving adjuvant chemotherapy for colorectal cancer. The study suggests that obese ...
A new study published in Proceedings of the National Academy of Sciences suggests that surgery should precede chemotherapy for certain patients with ovarian cancer. The research used a mathematical model to examine treatment outcomes and found that complete debulking surgery followed by chemotherapy provides better results. For patient...
Researchers at Washington University in St. Louis have developed a predictive model using tumor biomarkers and imaging parameters to forecast chemotherapy response. The model's accuracy reaches 0.94, allowing for early adjustments to treatment plans and reduced use of toxic chemotherapy drugs.
A biomarker based on circulating tumour DNA (ctDNA) can predict the likelihood of bowel cancer recurrence after surgery and chemotherapy. The test measures ctDNA levels before and after treatment to provide real-time information on chemotherapy effectiveness.
The ECOG-ACRIN Cancer Research Group presented new research results on patients with breast and HPV-associated throat cancers. A phase III trial found platinum chemotherapy ineffective in preventing recurrence of basal-like triple-negative breast cancer, while a study on severe joint pain in postmenopausal women with hormone receptor-p...
Researchers from NUS Cancer Science Institute have discovered a link between high levels of DNA repair protein RAD51 and platinum chemotherapy resistance in ovarian cancer patients. This finding could help identify patients who may require novel immunotherapy approaches to improve treatment outcomes.
Researchers have developed a prognostic and therapeutic epigenetic biomarker for PDAC patients, predicting which are likely to benefit from traditional chemotherapy. The technology addresses a pressing clinical need by introducing the first ever epigenetic precision medicine approach to pancreatic cancer.
Researchers identified DUSP16 as a protein that promotes chemotherapy resistance in four types of cancer. Elevated DUSP16 levels can lead to reduced treatment effectiveness, highlighting its potential use as a biomarker for sensitivity to chemotherapy.
Researchers at Linköping University and Medical University of Graz developed an ion pump that can deliver chemotherapy agents like gemcitabine directly into the brain with high precision. This method may provide a more effective treatment for glioblastoma, a type of brain tumor.
Research from Queen Mary University of London reveals that chemotherapy activates immune cells within the tumor microenvironment to fight against cancer. Macrophages switched from pro-tumour to anti-tumour mode after chemotherapy, stimulating patient's immune response and potentially improving survival outcomes.
A new pilot study suggests that restricting calories, reducing fat and sugar intake, and increasing physical activity can improve the effectiveness of chemotherapy for older children and adolescents with leukemia. The intervention showed promise in reducing minimal residual disease, a strong predictor of relapse.
A new study from the University of Arizona Department of Surgery found that pancreatic cancer patients who undergo chemotherapy followed by resection live an average of 19.75 months, compared to 10.12 months for those who received only chemotherapy. The researchers suggest that surgery can improve survival even in difficult cases.
Researchers at the University of Queensland have discovered that an anti-inflammatory drug called anakinra can reduce the awful nerve symptoms associated with vincristine chemotherapy. The study found that anakinra substantially reduced neuropathic pain without reducing the effectiveness of the treatment.
Researchers at Weill Cornell Medicine found that cancer cells can dodge chemotherapy by entering a state of hibernation, or senescence, which enables them to survive aggressive treatments. This discovery has implications for developing new drug combinations that could block senescence and make chemotherapy more effective.
Researchers assessed tumor cell isolation and in vitro proliferation assays to predict chemotherapy response in ovarian cancer. In 12 of 14 cases, in vitro drug sensitivity correlated with clinical outcome.
Researchers from Osaka University have identified the molecular mechanism underlying bone marrow regeneration after chemotherapy. They found that group 2 innate lymphoid cells produce granulocyte-macrophage colony-stimulating factor to aid in HSPC recovery, and their transfer accelerates hematopoietic recovery.
A recent study has identified potential risk factors for chemotherapy-induced peripheral neuropathy (CIPN), including age, body mass index (BMI), and low haemoglobin levels. Patients who are older, overweight, or have lower red blood cell counts may be more at risk of developing debilitating nerve damage following chemotherapy.
A new class of antibiotic-drug conjugate (ADC) drugs has been found to significantly increase the survival rate of patients with bladder cancer. The study, led by Queen Mary University of London, showed that the drug reduced the risk of death by 30% compared to chemotherapy, with a median survival time of approximately 13 months.
Groundbreaking evidence reveals scalp cooling reduces chemotherapy drug absorption by hair follicle cells. This mechanism explains the treatment's cytoprotective effect and supports its clinical efficacy. The study provides new insights into scalp cooling's potential for reducing hair loss in cancer patients.
A randomized clinical trial found that pre-surgery chemotherapy did not improve survival rates in early-stage pancreatic cancer patients, but it is a safer alternative. The study paved the way for further treatment testing and molecular analysis of tumor tissue.
Research at Charité - Universitätsmedizin Berlin found that patients' immune systems before chemotherapy determine treatment success in bladder cancer. High levels of CXCL11 and CXCR3alt receptors indicate a strong immune response, leading to increased survival rates.
Researchers have found that cancer cells can enter a slow-dividing state to survive chemotherapy, similar to an embryonic survival program in mammals. Targeting these sleeping cells with novel therapies may prevent cancer regrowth and overcome drug resistance.
A new UCL study found that combining heat treatment with chemotherapy delivered via magnetic nanoparticles killed cancer cells more effectively than chemotherapy alone. The therapy showed synergistic effects, enhancing the effectiveness of both treatments when combined. Heat treatment can reduce side effects by targeting only cancer ce...
A new study from the University of East Anglia estimates that breast cancer chemotherapy in the UK results in over £248 million in annual costs. These costs include lost productivity and personal expenses such as wigs and medication. Better targeting of treatment could help reduce these unnecessary costs.
A team of researchers has identified a protein called RFWD3 that plays a critical role in recruiting DNA repair and signaling factors. The discovery could lead to new methods to inhibit these repair processes, making chemotherapy more efficient and reducing side effects.
Researchers found that adding an immune checkpoint inhibitor to standard chemotherapy for patients with early-stage breast cancer does not decrease their ability to perform daily activities. The study, based on data from the IMpassion031 trial, showed increased response rates and no significant impact on quality of life.
A new clinical trial suggests that postmenopausal patients with hormone receptor-positive and HER2-negative breast cancer and a low recurrence score of 25 or lower may safely avoid chemotherapy. In contrast, premenopausal patients who receive chemotherapy show improved invasive disease-free survival and overall survival rates.
A clinical trial found that postmenopausal women with low-risk breast cancer can forego chemotherapy without compromising their treatment outcomes. In contrast, premenopausal women with the same disease characteristics benefit from chemotherapy, suggesting a potential age-related difference in treatment effectiveness.
The EA2176 study aims to enroll 205 patients in the US with inoperable advanced squamous cell anal cancer, comparing standard chemotherapy with or without nivolumab. The trial seeks to determine if adding immunotherapy will prolong progression-free survival and reduce symptoms.
Researchers found that administering immunotherapy in combination with chemotherapy earlier in the course of disease can slow cancer progression. Combining the therapies also kills myeloid-derived suppressor cells, which appear to overpower immunotherapies, thereby improving response rates.
A Purdue University scientist is working on a technique that uses LED light to determine if certain chemotherapy options will work for specific patients. The method, which was published in Scientific Reports, shows promise for improving personalized medicine and reducing side effects.
A new study suggests that gut bacteria are partially responsible for metabolic changes leading to weight gain in women after chemotherapy treatment. The research found that the pre-treatment microbiome of patients who gained weight was different from those who did not, and fecal transplantation resulted in glucose intolerance in germ-f...
Researchers found a pattern of gut bacteria, specifically SCFAs, that may influence the effectiveness of chemotherapy in breast cancer patients. These chemicals play a role in the immune system and may help patients mount an immune response against cancer cells.
Researchers from CU published a paper on ovarian cancer tumor composition changes during chemotherapy, revealing potential biomarkers for therapeutic response. The team aims to improve prediction of patient response to chemotherapy using multi-spectral immunohistochemistry and transcriptomics.
Researchers at City of Hope found that Andrographis paniculata, a natural botanical, is effective in killing chemo-resistant colon cancer cells when used in conjunction with chemotherapy. The study's goal was to develop a non-toxic treatment that could succeed in killing cancer cells.
Researchers have used single-cell RNA sequencing to profile transcriptome-level changes in response to DNA damage across individual cancer cells. The study found three distinct groups of genes activated in response to chemotherapy, revealing new insights into why some cancer cells survive while others die.
The combination of first-line nivolumab and ipilimumab demonstrated an improvement in overall survival compared to platinum-based chemotherapy for patients with unresectable malignant pleural mesothelioma. The study showed a two-year overall survival rate of 40.8% for the treatment arm vs 27.0% for the chemotherapy arm.
A new study uses patient-specific tumor organoids to identify the most effective chemotherapy protocol for treating advanced stages of colon and appendiceal cancer. The approach shows promise in tailoring treatment to individual patients, potentially increasing life expectancy.
Researchers found that chemotherapy is rarely used to treat adults with localized sarcoma, affecting only 22% of patients. Facilities performing more surgeries for sarcoma tend to use chemotherapy more frequently.
Researchers at MU successfully treated bone cancer in dogs with a vaccine that stimulates the immune system against abnormal proteins specific to the patient's tumor. The treatment outperformed chemotherapy, resulting in over 400 days of cancer survival for dogs compared to about 270 days for those receiving traditional chemotherapy.
Researchers at Hokkaido University found that inflammatory changes in tumors caused by chemotherapy trigger drug resistance in blood vessels, resulting in poorer cancer outcomes. The team also discovered a treatment strategy involving the combination of an ABCB1 inhibitor and anticancer drugs to overcome this resistance.
Researchers have identified a promising new strategy to target tumors with metabolic weaknesses, particularly in patients with IDH mutant gliomas. Combining chemotherapy and PAR glycohydrolase inhibitors has shown promise in enhancing treatment effectiveness.
A new class of precision medicine targeting cancer's ability to repair its DNA has shown promising results, with half of patients experiencing tumor growth halt. The drug works by stopping cancers from repairing DNA damage and is particularly effective when combined with chemotherapy.
UConn researchers use patented nanoparticle with common chemotherapy drug doxorubicin to target leukemia stem cells, reducing treatment-resistant relapses. The nanoparticle enables slow release of the drug to bone marrow, improving survival rates and inhibiting cancerous stem cells.
Researchers from the University of South Australia suggest that Vitamin D could mitigate chemotherapy-induced intestinal mucositis by suppressing inflammation and enhancing T-cell function. The study highlights the potential benefits of Vitamin D in reducing damage to the gut microbiome caused by chemotherapy agents.
In a phase 2 trial, berzosertib, an ATR protein inhibitor, was found to significantly extend progression-free survival for patients with ovarian cancer compared to chemotherapy alone. The drug targets a protein crucial for cancer cell growth and division.
A new study reveals that chemotherapy and cancer contribute to the development of neuropathy, a condition affecting millions of cancer patients. Researchers found that cancer itself causes significant distress to neurons, while chemotherapy amplifies this effect, leading to more severe trauma.
A new algorithm has been developed to select breast cancer patients in need of urgent surgery or chemotherapy during the COVID-19 pandemic. The algorithm uses data from international trials to identify postmenopausal patients with primary ER+HER2- breast cancer who have less endocrine-sensitive tumours and should be prioritized for ear...
Dietary changes can trigger changes in the host's response to chemotherapy drugs, increasing or decreasing their effectiveness and toxicity. Researchers found that common components of daily diets can have a profound impact on cancer treatment outcomes.
A phase III clinical trial found that the addition of cediranib to olaparib and standard platinum-based chemotherapy did not improve progression-free survival outcomes, but showed similar activity in patients. The study suggests potential for non-platinum based alternatives in certain biomarker subgroups.
A large international trial found that pembrolizumab more than doubled the progression-free survival time of patients with a specific subtype of advanced bowel cancer, compared to chemotherapy. The treatment also showed durable benefits, with 48.3% of patients experiencing no disease progression after two years.
Researchers from SWOG will make 31 digital presentations at the ASCO20 Virtual Scientific Program, reporting on trials involving chemotherapy regimens, financial toxicity, and multiple myeloma treatments. The studies found that pre-surgery chemotherapy can be done safely and has good outcomes regardless of the drugs used.
A clinical trial led by Mount Sinai researchers showed that combining chemotherapy and immunotherapy can significantly delay the progression of metastatic bladder cancer. The trial also found that immunotherapy alone may be an option for patients with high PD-L1 protein expression in their tumors.
A research team at Pohang University of Science & Technology has developed an integrative cancer therapy using adoptive natural killer cell therapy and chemotherapy. The new method enhances the effectiveness of cell therapy in treating solid cancers by selectively releasing anticancer drugs, reducing side effects.
Dexrazoxane has been shown to preserve cardiac function and reduce risk of severe cardiac events in pediatric patients undergoing chemotherapy for acute myeloid leukemia (AML). The study suggests dexrazoxane should be considered for cardioprotection in all pediatric patients undergoing standard chemotherapy for AML.
A new study led by Yale Cancer Center researchers shows that immunotherapy prior to surgery can increase the rate of complete eradication of high-risk HER2-negative breast cancer from the breast and lymph nodes. The treatment combination of durvalumab, a checkpoint inhibitor, with chemotherapy resulted in a higher pCR rate compared to ...